Micromet makes additions to its advisory panel
This article was originally published in Scrip
Micromet, a biopharmaceutical company developing novel proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, has appointed Sir Walter Bodmer and Bernard Fox to its BiTE antibody advisory panel. Micromet's novel antibody technology is based on its proprietary BiTE antibody platform, and represents a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease-related cells.
You may also be interested in...
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.